Previous Close | 0.0150 |
Open | 0.0000 |
Bid | 0.0100 x N/A |
Ask | 0.0150 x N/A |
Day's Range | 0.0150 - 0.0150 |
52 Week Range | 0.0050 - 0.0700 |
Volume | |
Avg. Volume | 31,868 |
Market Cap | 1.116M |
Beta (5Y Monthly) | 4.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Albert Labs International Corp. (CSE: ABRT) (the "Company" or "Albert Labs"), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs, is pleased to announce the preliminary acceptance of 35 novel inventive claims to comply with PCT 33(3) under its International PCT Patent Application (No. PCT/CA2022/051281).